Healthcare / BiotechnologyNasdaqGS
$7.64
+0.32 (+4.37%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-125.3M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$74M
P/E
11.9x
↓EV/EBITDA
10.7x
↓ROE
12.9%
↑Gross Margin
-729.4%
↓Debt/Equity
1.88
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
109.6%
FCF / Net income
0.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $789000.0 · net income $5.7M · FCF $865000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | $789000.00 | $789000.00 | — | — | — | $143.9M | $11.9M | $27.2M | $26.9M | $32.1M | $21.8M | $0.00 | — | — |
| Net Income | $5.7M | $5.7M | $136000.00 | $-113.7M | $-250.2M | $-65.6M | $-89.1M | $-70.3M | $-98.9M | $-89.4M | $-91.6M | $-54.8M | $-16.7M | $-6.1M |
| EBITDA | $9.8M | $9.8M | $-120.3M | $-181.4M | $-170.9M | $-58.5M | $-81.6M | $-64.3M | $-92.4M | $-84.1M | $-88.6M | $-54.1M | $-14.9M | $-6.0M |
| EPS | 0.64 | 0.64 | — | -17.77 | -46.20 | -14.40 | -22.40 | — | — | — | — | — | — | — |
| Gross Margin | -729.4% | -729.4% | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -11910.1% | -11910.1% | — | — | — | -44.8% | -740.8% | -264.4% | -372.6% | -284.7% | -426.5% | — | — | — |
| Net Margin | 721.9% | 721.9% | — | — | — | -45.6% | -749.2% | -258.5% | -367.6% | -278.4% | -420.7% | — | — | — |
| Balance Sheet | ||||||||||||||
| Debt/Equity | 1.88 | 1.88 | 6.65 | -4.43 | 15.08 | 0.18 | 0.14 | -0.52 | — | — | — | — | — | — |
| Current Ratio | 1.65 | 1.65 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $865000.00 | $865000.00 | $-149.0M | $-125.3M | $-238.6M | $-2.9M | $-94.2M | $-77.5M | $-64.8M | $-80.2M | $22.4M | — | — | — |
| Returns | ||||||||||||||
| ROE | 12.9% | 12.9% | 1.0% | 253.5% | -2319.9% | -49.9% | -51.0% | 145.4% | 205.9% | -147.3% | -69.0% | -26.7% | 62.5% | 54.9% |
| Valuation | ||||||||||||||
| P/E | 11.94 | 11.94 | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 10.68 | 10.68 | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 1.53 | 1.53 | 10.20 | — | 54.12 | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||
| Revenue Growth | — | — | — | — | — | 1109.2% | -56.2% | 1.0% | -16.1% | 47.5% | — | — | — | — |
| EPS Growth | — | — | — | 61.5% | — | 35.7% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
1.9%
EPS terminal req.
$0.68
Spread vs growth
n/d
5Y implied EPS CAGR
5.1%
EPS terminal req.
$0.82
Spread vs growth
n/d
10Y implied EPS CAGR
7.5%
EPS terminal req.
$1.32
Spread vs growth
n/d
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+8.4%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → 0.64
Residual
+8.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.